Matteo Morotti, Medical program leader at CDR-Life, shared on X/Twitter:

“Proud to share the results of our study on the effect of prostaglandin E2 on T cells, which was just published in Nature in which we discovered a new role for PGE2 in inhibiting interleukin-2 (IL-2) sensing and signalling in tumor-reactive T cells.

This could have a significant therapeutic impact for cancer immunotherapy using both endogenous (immune-checkpoint, T cell engagers, TIL therapy) and synthetic immunity (CAR-T) as blocking this pathway can resensitize T cells to IL-2 and improve their antitumour potential.

Special thank to Alizee Grimm and Denada Dangaj, Institute of Molecular Immunology, Jan P. Böttcher.
All of our friends and colleagues who worked with us, funders and patients who supported these trials and research, and, of course, George Coukos for his vision!

And grateful to all our collaborators HoLab, Vannini Lab, Jesus Corria-Osorio, and also all the others twitter-free.

And also thank to The Conrad Lab and team for his advices on ferroptosis.

And the super Helen Carrasco Hope.!!!”

Source: Matteo Morotti/X